DexCom (NASDAQ:DXCM) Director Sells $60,730.12 in Stock

DexCom, Inc. (NASDAQ:DXCM) Director Bridgette Heller sold 1,012 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total transaction of $60,730.12. Following the completion of the transaction, the director directly owned 25,007 shares of the company’s stock, valued at $1,500,670.07. The trade was a 3.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Price Performance

DXCM stock traded down $0.75 during trading on Thursday, hitting $57.82. The stock had a trading volume of 4,306,023 shares, compared to its average volume of 4,980,691. The company’s 50 day moving average price is $63.99 and its two-hundred day moving average price is $66.01. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $89.98. The stock has a market cap of $22.31 billion, a price-to-earnings ratio of 24.71, a price-to-earnings-growth ratio of 1.05 and a beta of 1.40. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the company posted $0.32 EPS. The firm’s revenue for the quarter was up 15.0% on a year-over-year basis. On average, sell-side analysts forecast that DexCom, Inc. will post 2.56 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on DXCM. Robert W. Baird set a $80.00 target price on shares of DexCom in a research note on Friday, May 1st. Wells Fargo & Company dropped their price objective on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a research note on Friday, February 13th. Benchmark assumed coverage on shares of DexCom in a research note on Monday. They set a “buy” rating and a $77.00 price objective for the company. Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Finally, Evercore raised shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price objective for the company in a research note on Tuesday, March 24th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $83.22.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of DXCM. Brighton Jones LLC increased its stake in shares of DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after acquiring an additional 11,946 shares during the last quarter. Integrated Wealth Concepts LLC increased its stake in shares of DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after acquiring an additional 196 shares during the last quarter. Empowered Funds LLC increased its stake in shares of DexCom by 5.4% during the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after acquiring an additional 436 shares during the last quarter. Focus Partners Wealth grew its holdings in shares of DexCom by 13.2% during the 1st quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after purchasing an additional 841 shares during the period. Finally, NewEdge Advisors LLC increased its position in DexCom by 1.4% during the 2nd quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock worth $1,681,000 after purchasing an additional 258 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.